Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 3, 2013, Pages

  Li, Xi ^a   Xu, Shuangnian ^a   Tan, Ya ^a   Chen, Jieping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; MITOXANTRONE;

ACUTE MYELOID LEUKEMIA; ARTICLE; COMPARATIVE STUDY; DATA EXTRACTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 85041518696     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010432     Document Type: Article

References (60)

1. AML Collaborative Group. A systematic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. British Journal of Haematology 1998;103(1):100-9.
2. Arcamone F, Bernardi L, Giardino P, Patelli B, Marco A, Casazza AM, et al.Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9-diepidaunorubicin, and their beta anomers. Cancer Treatment Reports 1976;60(7):829-34.
3. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, et al.AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88(4):1390-8.
4. Beksac M, Arslan O, Koc H, Akan H, Ilhan O, Arat M, et al.Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. Medical Oncology 1998;15(3):183-90.
5. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, et al.Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Research 1983;43(12 Pt 1):6096-101.
6. Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, et al.4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Research 1989;49(2):477-81.
7. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al.Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77(8):1666-74.
8. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79(12):3267-73.
9. Berman E, Wiernik P, Vogler R, Velez-Garcia E, Bartolucci A, Whaley FS. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer 1997;80(11 Suppl):2181-5.
10. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology 2011;29(5):487-94.
11. Carella AM, Santini G, Martinengo M, Marmont AM. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias. Haematologica 1984; Vol. 69, issue 6:767-8.
12. Carella AM, Martinengo M, Santini G, Gaozza E, Damasio E, Giordano D, et al.Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia. European Journal of Cancer and Clinical Oncology 1987;23(11):1673-8.
13. Casazza AM, Pratesi G, Giuliani F, Marco DA. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 1980;66(5):549-64.
14. Cersosimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clinical Pharmacy 1992;11(2):152-67.
15. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, et al.Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001; Vol. 15, issue 3:348-54.
16. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
17. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al.Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74.
18. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;88(1):308-13.
19. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11(10):1661-4.
20. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894-907.
21. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al.Anthracycline dose intensification in acute myeloid leukemia. The New England Journal of Medicine 2009;361(13):1249-59.
22. Ganzina F, Pacciarini MA, Di Pietro N. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Investigational New Drugs 1986;4(1):85-105.
23. Baer MR, Greer JP. Acute Myeloid Leukemia in Adults. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA editor(s). Wintrobe's Clinical Hematology. 12th Edition. Lippincott Williams & Wilkins, 2009.
24. Hande KR. Principles and Pharmacology of Chemotherapy. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA editor(s). Wintrobe's Clinical Hematology. 12th Edition. Lippincott Williams & Wilkins, 2009.
25. Harousseau JL, Hurteloup P, Reiffers J, Rigal-Huguet F, Hayat M, Dufour P, et al.Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treatment Reports 1987; Vol. 71, issue 10:991-2.
26. Harousseau JL, Pignon B, Witz F, Polin V, Tellier Z, Hurteloup P, et al.Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Hematology and Cell Therapy 1996; Vol. 38, issue 5:381-91.
27. Hayat M, Hurteloup P, Parmentier C, Carde P, Pico JO, Schlumberger M, et al.Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia. Investigational New Drugs 1984; Vol. 2, issue 4:375-9.
28. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data, In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
29. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
30. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Indrak K, Hubacek J, Mayer J, Voglova J, Jarosova M, Krahulova M, et al.Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75): a prospective multicenter randomized study conducted 1998-2000. Vnitrni Lekarstvi 2001;47 Suppl 1:48-56.
32. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clinic Proceedings 2006;81(2):247-60.
33. Johnson SA, Richardson DS. Anthracyclines in haematology: pharmacokinetics and clinical studies. Haematological Oncology 1998;12(1):52-71.
34. Kaplan S, Martini A, Varini M, Togni P, Cavalli F. Phase I trial of 4-demethoxydaunorubicin with single i.v. doses. European Journal of Cancer and Clinical Oncology 1982;18(12):1303-6.
35. Lambertenghi-Deliliers G, Maiolo AT, Annaloro C, Cortelezzi A, Pogliani E, Ganzina F, et al.Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia. European Journal of Cancer and Clinical Oncology 1987; Vol. 23, issue 7:1041-5.
36. Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A, et al.The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Annals of Oncology 1997;8(12):1273-5.
37. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34.
39. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al.The prevention and treatment of missing data in clinical trials. The New England Journal of Medicine 2012;367(14):1355-60.
40. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. The New England Journal of Medicine 1999;341(14):1051-62.
41. Lowenberg B, Ossenkoppele GJ, Van Putten W, Schouten HC, Graux C, Ferrant A, et al.High-dose daunorubicin in older patients with acute myeloid leukemia. The New England Journal of Medicine 2009;361(13):1235-48.
42. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, et al.A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. European Journal of Cancer 1991;27(6):750-5.
43. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al.Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. Journal of Clinical Oncology 2009;27(32):5397-403.
44. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
45. Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, et al.Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. International Journal of Hematology 2010;91(1):97-103.
46. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al.Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011;117(8):2358-65.
47. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
48. Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, et al.Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. British Journal of Haematology 1996;94(2):333-41.
49. Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, et al.A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996;10(3):389-95.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
51. Robert J, Rigal-Huguet F, Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematological Oncology 1992;10(2):111-6.
52. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al.A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103(2):479-85.
53. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Research 1977;37(12):4523-8.
55. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106(4):1154-63.
56. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trial 2007;8:16.
57. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al.A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Journal of Clinical Oncology 1992;10(7):1103-11.
58. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111(5):2505-15.
59. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al.Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79(2):313-9.
60. Zittoun RA, Mandelli F, Willemze R, Witte TD, Labar B, et al.Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. The New England Journal of Medicine 1995; Vol. 332, issue 4:217-23.